Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 11:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 3,386 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Pathologies Clear all

Conditions: Pain
Interventions: Normal saline as placebo comparator, Intravenous ibuprofen; Other · Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 12
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 6 more

Conditions: Cancer
Interventions: polymorphism analysis, laboratory biomarker analysis; Genetic · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: Not listed
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 3
States / cities: Nashville, Tennessee

Conditions: Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Oral Complications, Radiation Toxicity
Interventions: filgrastim, palifermin, cyclophosphamide, etoposide, ifosfamide, quality-of-life assessment, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 12 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Chronic Stress, Systemic Inflammation, Mobility and Independence
Interventions: Eutectogel Sensors and Microneedle Patches; Device
Lead sponsor: Tufts University; Other
Eligibility: 65 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Common Variable Immunodeficiency (CVID), Primary Immune Regulatory Disorder, Immune Dysregulation, DiGeorge Syndrome, STAT 1 Gain of Function, STAT 3 Gain of Function, Hypomorphic RAG1 Deficiency, CD40 Ligand Deficiency, Mendelian Susceptibility to Mycobacterial Disease, GATA2 Associated Immunodeficiency, CD40 Deficiency, Hypomorphic RAG2 Deficiency, Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome, Omenn Syndrome, Chronic Granulomatous Disease
Interventions: Hematopoietic stem cell transplant (HSCT); Biological
Lead sponsor: Paul Szabolcs; Other
Eligibility: 5 Years to 40 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Williams Syndrome, Angelman Syndrome, Prader-Willi Syndrome, Shprintzen Syndrome, Smith-Magenis Syndrome, DiGeorge Syndrome, Chromosome Abnormalities
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 0 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT; Biological · Drug · Procedure
Lead sponsor: Northside Hospital, Inc.; Other
Eligibility: Up to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Shock, Thermal Burn
Interventions: Ascorbic Acid, placebo; Drug
Lead sponsor: Clinical Evaluation Research Unit at Kingston General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 666 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 10
States / cities: Phoenix, Arizona • Bridgeport, Connecticut • Washington D.C., District of Columbia + 7 more

Conditions: Muscle Weakness, ICU-acquired Weakness
Interventions: HMB protein supplement (3g), Nutritional Supplement; Dietary Supplement
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 65 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Hermansky-Pudlak Syndrome (HPS), Pulmonary Fibrosis, Oculocutaneous Albinism, Platelet Storage Pool Deficiency, Metabolic Disease
Interventions: Losartan, Zileuton, N-Acetylcysteine, Pravastatin, Erythromycin; Drug
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Interventions: Odronextamab multiple dose levels; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 10
States / cities: Orange, California • Stanford, California • Tampa, Florida + 4 more

Conditions: Prostatic Neoplasms
Interventions: TAK-700; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 19
States / cities: Beverly Hills, California • Los Angeles, California • Aventura, Florida + 8 more

Conditions: Myeloma, Plasma-Cell, Lymphoma, Malignant
Interventions: Palonosetron, Aprepitant, Dexamethasone; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Chronic Periodontitis
Interventions: LANAP; Device
Lead sponsor: Institute for Advanced Laser Dentistry; Other
Eligibility: 25 Years to 75 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Central Visual Impairment, Macular Degeneration
Interventions: Training visual sensitivity, Combination training; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 89 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Depression, Anxiety, Eating Disorders, Drug Use Disorders
Interventions: standardized diagnostic assessment, self-report questionnaires, behavioral tasks, physiological measurements, structural and functional magnetic resonance imaging and EEG, biomarker and microbiome assessments, blood to derive induced pluripotent stem cells, genetic and epigenetic assessments; Behavioral · Other
Lead sponsor: Laureate Institute for Brain Research, Inc.; Other
Eligibility: 18 Years to 55 Years
Enrollment: 1,271 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Leukemia, Myeloid, Chronic, Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome, Leukemia, Lymphocytic, Acute, Leukemia, Lymphocytic, Chronic, AML
Interventions: Donor Lymphocyte Infusion, Induction Chemotherapy; Procedure · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 1 Year to 70 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Bardet-Biedl Syndrome, POMC Deficiency
Interventions: Setmelanotide 2 mg, Setmelanotide 2.5 mg, Setmelanotide 3 mg, Setmelanotide 20 mg, Setmelanotide 25 mg, Setmelanotide 30 mg; Drug
Lead sponsor: Rhythm Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Scottsdale, Arizona • Marshfield, Wisconsin

Conditions: Head and Neck Cancer, Human Papilloma Virus
Interventions: MEDI0457, CELLECTRA®5P device, Durvalumab; Drug · Device
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 14
States / cities: San Francisco, California • Orlando, Florida • Atlanta, Georgia + 10 more

Conditions: Bariatric Surgery Candidate, Cardiovascular Diseases, Type 2 Diabetes, Dyslipidemias, Hypertension, Morbid Obesity
Interventions: Bariatric Surgery; Procedure
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 21 Years to 65 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2035
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Pregnant Individuals, Aneuploidy, Down Syndrome (Trisomy 21), 22q11.2 Deletion Syndrome, Trisomy 13, Trisomy 18, Sex Chromosome Abnormalities
Interventions: Not listed
Lead sponsor: BillionToOne Inc.; Industry
Eligibility: Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 9
States / cities: Phoenix, Arizona • Riverside, California • West Covina, California + 5 more

Conditions: Degenerative Disc Disease
Interventions: Adipose Stem Cells; Procedure
Lead sponsor: Bioheart, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Sunrise, Florida

Conditions: COPD
Interventions: Standard oxygen delivery system, Homefill oxygen delivery system, Helios oxygen delivery system, FreeStyle oxygen system; Device
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: Not listed
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Asthma
Interventions: albuterol sulfate inhalation aerosol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: Up to 23 Months
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 27
States / cities: Hoover, Alabama • Fort Mohave, Arizona • Jonesboro, Arkansas + 24 more

Search by objective public record fields.

Trial of Caldolor for Treatment of Pain in Post-Operative Adult Patients

Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant

Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer

Assessing the Feasibility of Multi-modal Biosensing for Monitoring Mobility and Cognition in Older Adults

Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)

Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

VItamin C in Thermal injuRY: The VICToRY Trial

Improving Muscle Function in Nutritionally at Risk, Elderly Patients

Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome

Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

Safety Study of TAK-700 in Subjects With Prostate Cancer.

Multi-day Doses in Prevention of Nausea and Emesis

Study to Compare Laser Assisted New Attachment Procedure (LANAP) to Traditional Treatments of Chronic Periodontitis

Factors in Learning And Plasticity: Macular Degeneration

Latent Structure of Multi-level Assessments and Predictors of Outcomes in Psychiatric Disorders

Post Transplant Donor Lymphocyte Infusion

Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway

Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer

Gut Microbiota in Metabolic Surgery

The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to Non-invasive Fetal Risk Assessment

Adipose Cells for Degenerative Disc Disease

Prospective Study Comparing Different Modalities of Oxygen Delivery During Assessment of Functional Exercise Capacity

Inhaled Albuterol Sulfate For Acute Wheezing Due To Obstructive Airways Disease In Children